Human adipocytes stimulate invasion of breast cancer MCF-7 cells by secreting IGFBP-2. [PDF]
PLoS ONE, 2015 A better understanding of the effects of human adipocytes on breast cancer cells may lead to the development of new treatment strategies. We explored the effects of adipocytes on the migration and invasion of breast cancer cells both in vitro and in vivo.
Chen Wang +4 more
doaj +1 more source
Hierarchy of Gene Expression Data is Predictive of Future Breast Cancer Outcome [PDF]
, 2013 We calculate measures of hierarchy in gene and tissue networks of breast cancer patients. We find that the likelihood of metastasis in the future is correlated with increased values of network hierarchy for expression networks of cancer-associated genes,
Chen, Man, Deem, Michael W.
core +1 more source
Metastatic Breast Cancer to the Urinary Bladder in the Caribbean
Case Reports in Oncology, 2021 One of the most common cancers amongst women is breast cancer. The most common metastatic sites are the lymph nodes, lungs, liver, and bone. Metastatic spread to the urinary bladder is rare, and this case, as far as we are aware, is the first reported in
Saara Mohammed, Atiba Akii Bua
doaj +1 more source
Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes [PDF]
, 2012 mRNA levels of the urokinase receptor splice variant uPAR-del4/5 are associated with prognosis in breast cancer. Its overexpression in cancer cells affects tumor biologically relevant processes.
Baretton, Gustavo +10 more
core +1 more source
The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells [PDF]
, 2016 The angiogenic inducer CCN1 (Cysteine-rich 61, CYR61) is differentially activated in metastatic breast carcinomas. However, little is known about the precise mechanisms that underlie the pro-metastatic actions of CCN1. Here, we investigated the impact of
Espinoza, Ingrid +3 more
core +1 more source
Novel HER2–targeted therapies for HER2–positive metastatic breast cancer
Cancer, 2020 Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% of all breast cancers. Before the development of HER2‐directed monoclonal antibodies, HER2–positive breast cancer was associated with a rather poor prognosis.
S. Kunte, J. Abraham, A. Montero
semanticscholar +1 more source
Metastatic breast cancer: an updating
Biomedicine & Pharmacotherapy, 2006 This article reports on recent advances on metastatic breast cancer. Detection, prognostic factors, predictors of response to therapy and therapy, with particular regard to targeted therapies, were examined.Unlike current guidelines that yet do not routinely recommend intensive clinical-instrumental post-operative follow-up of breast cancer patients ...
NICOLINI, ANDREA +10 more
openaire +4 more sources
Nature Communications, 2022 Mortality from breast cancer is almost exclusively a result of tumor metastasis and resistance to therapy and therefore understanding the underlying mechanisms is an urgent challenge. Chemotherapy, routinely used to treat breast cancer, induces extensive
Lea Monteran +9 more
semanticscholar +1 more source
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. [PDF]
, 2016 BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies.
Cortes, Javier +10 more
core +2 more sources
Theranostics, 2021 Rationale: Breast cancer preferentially develops osteolytic bone metastasis, which makes patients suffer from pain, fractures and spinal cord compression.
Xinxin Yuan +27 more
semanticscholar +1 more source